[The best of vascular medicine in 2005].
It is illusory to think that one year is long enough to establish all the truths that will guide our clinical practice in vascular medicine. On the contrary, one year was long enough to contradict what the preceding twelve months had set out to demonstrate. Consequently, promising trials in the treatment of abdominal aortic aneurysms by endoprostheses have been the object of contradictory debate with regards to the long-term benefits. In fundamental research, circulating progenitors of endothelial cells have been shown to be a marker of atherosclerosis, but is it a better marker than LDL-cholesterol values? The demonstration that these progenitors are of value in the treatment of essential ischaemia of the lower limbs is awaited. Finally, ximelagatran, a direct thrombin antagonist, seemed to have all the qualities of an ideal anticoagulant: easy to use, safe... until the report of raised hepatic enzymes, the clinical relevance of which remains to be determined. In the good news section: the Systolic Pressure Index, an unquestioned marker of arterial disease. Its reduction was known to be correlated with the prevalence of cardiovascular complications. However, it has now been shown that an increase in the index is also associated with cardiovascular complications, a real U-shaped curve. Renal arterial stenosis should be considered in patients with left ventricular failure presenting with flash pulmonary oedema. In the absence of cardiac pathology, BNP would seem to be a good biological marker of haemodynamically significant renal arterial stenosis. Finally, should superficial femoral artery stenosis be treated by an active stent. To date, there is no formal proof.
Service de médecine vasculaire et HTA, Hôpital cardiologique, CHRU, 59037 Lille. cmouniervehier@chru-lille.fr
C
C
Mounier-Vehier
D
D
Stephan
F
F
Becker
J P
JP
Beregi
S
S
Haulon
S
S
Kownator
P
P
Marboeuf
M A
MA
Sevestre
J
J
Constans
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D018618:Echocardiography, Doppler, Color; D006801:Humans; D011643:Publishing / Q000639:trends; D015607:Stents; D014652:Vascular Diseases / Q000000981:diagnostic imaging / Q000628:therapy*
D020533:Angiogenesis Inhibitors; D000925:Anticoagulants